Table 3 Incidence of grade ≥ 3 DRAEs in patients from KEYNOTE-001 and KEYNOTE-006
From: Pembrolizumab
AE, % | Nonrandomized and randomized cohorts | NSCLC cohorts | KEYNOTE-006 | KEYNOTE- 006 |
|---|---|---|---|---|
(n = 411) [16] | (n = 495) [22] | (melanoma, 10 mg/kg Q2W, n = 278) [21] | (melanoma,10 mg/kg Q3W, n = 277) [21] | |
Fatigue | 2 | <1 | 0 | <1 |
ALT increase | <1 | <1 | 0 | <1 |
Colitis | <1 | NR | 1 | 3 |
Decreased appetite | <1 | 1 | 0 | 0 |
Diarrhea | <1 | <1 | 3 | 1 |
Dyspnea | <1 | 4 | 0 | <1 |
Headache | <1 | NR | 0 | 0 |
Hepatitis | <1 | NR | 1 | 2 |
Hyperthyroidism | <1 | NR | 0 | 0 |
Hypophysitis | <1 | NR | <1 | <1 |
Hypothyroidism | <1 | <1 | <1 | 0 |
Nausea | <1 | <1 | 0 | <1 |
Pneumonitis | <1 | 2 | 0 | <1 |
Pruritus | <1 | 0 | 0 | 0 |
Rash | <1 | <1 | 0 | 0 |
Arthralgia | 0 | <1 | 0 | <1 |
Asthenia | 0 | 1 | <1 | 0 |